NCT03980938View on ClinicalTrials.gov

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

October 15, 2020

Study Completion Date

October 15, 2020

Conditions
Huntington Disease
Interventions
DRUG

neflamapimod

40 mg neflamapimod capsule

OTHER

Placebo

matching placebo capsule

Trial Locations (1)

CB2 0PY

John Van Geest Centre for Brain Repair, Cambridge

Sponsors

Lead Sponsor

EIP Pharma Inc
All Listed Sponsors
collaborator

Voisin Consulting, Inc.

INDUSTRY

lead

EIP Pharma Inc

INDUSTRY

NCT03980938 - Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease | Biotech Hunter | Biotech Hunter